Physician profile
Mark S Ledoux
NPI 1407813439
$351,587.16
in general payments reported to CMS, 2019-2025
34 companies · $44K in 2025
The $44K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $47K · 2021: $30K · 2022: $76K · 2023: $22K · 2024: $42K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Honoraria: $33K · Travel and Lodging: $5,107 · Food and Beverage: $2,477 · Education: $1,559 · Consulting Fee: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,566.63 |
| Honoraria | $33,003.00 |
| Travel and Lodging | $5,107.08 |
| Food and Beverage | $2,476.71 |
| Education | $1,558.95 |
| Consulting Fee | $705.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $157,900.09 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $69,402.10 | 2020-2025 | Crexont, Ongentys, Ongentys 50mg Capsules 30 |
| Mdd US Operations, LLC | $40,123.70 | 2019-2024 | Apokyn, Gocovri |
| Kyowa Kirin, INC. | $32,287.94 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $28,446.66 | 2019-2022 | |
| Acorda Therapeutics, INC | $17,029.50 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $3,726.65 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $1,549.87 | 2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $191.04 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $124.09 | 2019-2022 | |
| Emd Serono, INC. | $122.68 | 2019 | |
| Medtronic USA, INC. | $106.23 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $85.56 | 2019 | |
| Lundbeck LLC | $68.01 | 2019 | |
| Abbvie INC. | $65.71 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $59.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $50.36 | 2019 | |
| Biogen, INC. | $37.28 | 2020 | |
| Merz Pharmaceuticals, LLC | $31.14 | 2025 | Xeomin |
| Medtronic, INC. | $19.83 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.92 | 2019 | |
| Lilly USA, LLC | $18.92 | 2019 | |
| Ge Healthcare | $17.30 | 2023 | |
| Adamas Pharmaceuticals, INC. | $17.23 | 2021 | |
| Abbott Laboratories | $15.47 | 2023 | Infinity |
| Boston Scientific Corporation | $15.33 | 2022 | |
| Revance Therapeutics, INC. | $14.35 | 2025 | Daxxify |
| Jazz Pharmaceuticals INC. | $14.23 | 2019 | |
| Allergan, INC. | $13.96 | 2020 | |
| Avion Pharmaceuticals | $13.68 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ledoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.